Heart health medication for kidney transplant patients
Treatments studied
Part of Heart & circulation, Kidney & urinary clinical trials.
This trial tests whether eplerenone (a blood pressure pill) can improve heart function in people who have had a kidney transplant and are taking cyclosporine or tacrolimus. It may help reduce the strain on the heart caused by these anti-rejection medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have had a kidney transplant at least 1 year ago, and less than 5 years ago.
- You are currently taking cyclosporine or tacrolimus (anti-rejection medicines).
- Your kidney function is stable, and your kidney function test (GFR) is 40 or higher.
- Your blood pressure is at least 110 mmHg (systolic), with or without medication.
- An ultrasound of your heart shows some thickening or enlargement (left ventricular mass or left atrial volume above a certain level).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a once-daily anti-rejection medicine (Envarsus) works in people who have just had a kidney transplant. It helps doctors understand the best way to use this medicine and manage side effects.
This trial tests whether eplerenone can slow the progression of blood vessel (vasculature) problems in people who have had a kidney transplant. You may be eligible if you are older, stable on your transplant medicines, and have higher peripheral artery blood pressure readings.
This trial tests a new treatment for people with heart failure and severely reduced kidney function. It aims to see if the treatment can help protect both the heart and kidneys.
This Phase 2 study tests whether eplerenone can improve outcomes after a heart attack (or similar heart injury) when coronary angiography shows no blocked heart arteries. It focuses on people with added cardiovascular risk factors and evaluates how well the treatment works for heart recovery and strain on the heart.
This study tests whether a medicine called eplerenone can help prevent atrial fibrillation from coming back in people who also have structural heart disease (changes in the heart's structure). If you have had episodes of irregular heartbeat that stopped, this drug might lower the chance of them returning.
This study looks at how mineralocorticoid-related hormone signaling affects small heart blood vessels and how efficiently the heart works in people with high blood pressure. It may help doctors understand which treatments could improve heart function in hypertension.
Hear when a new Kidney Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.